Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-05 14:59 |
Form 6-K- Fourth quarter and full year 2023 results
|
English | 181.2 KB | ||
| 2024-03-05 14:59 |
Form 6-K- Fourth quarter and full year 2023 results
|
English | 36.4 KB | ||
| 2024-02-26 14:59 |
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
|
English | 93.4 KB | ||
| 2024-02-26 14:59 |
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
|
English | 36.2 KB | ||
| 2024-02-20 14:59 |
to Release Fourth Quarter and Full Year 2023 Results on
Tuesday, March 5, 2024,…
|
English | 83.0 KB | ||
| 2024-02-20 14:59 |
to Release Fourth Quarter and Full Year 2023 Results on
Tuesday, March 5, 2024,…
|
English | 36.4 KB | ||
| 2024-02-15 14:59 |
Appointment of Michelle Mahler M.D. as Chief Medical Officer
|
English | 73.1 KB | ||
| 2024-02-15 14:59 |
Appointment of Michelle Mahler M.D. as Chief Medical Officer
|
English | 36.2 KB | ||
| 2024-01-08 15:09 |
Form 6-K-Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement;…
|
English | 77.9 KB | ||
| 2024-01-08 15:09 |
Form 6-K-Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement;…
|
English | 36.3 KB | ||
| 2024-01-08 15:04 |
Compugen to Receive $10 Million Milestone Payment Following
Dosing of First Pat…
|
English | 90.9 KB | ||
| 2024-01-08 15:04 |
Compugen to Receive $10 Million Milestone Payment Following
Dosing of First Pat…
|
English | 36.3 KB | ||
| 2024-01-08 14:59 |
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
English | 85.1 KB | ||
| 2024-01-08 14:59 |
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
English | 36.3 KB | ||
| 2023-12-19 15:11 |
6K-License Agreement with Gilead and entitlement to receive a milestone payment…
|
English | 257.8 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
